QUINIDINE KINETICS AFTER A SINGLE ORAL DOSE IN RELATION TO THE SPARTEINE OXIDATION POLYMORPHISM IN MAN

被引:27
作者
BROSEN, K
DAVIDSEN, F
GRAM, LF
机构
[1] Department of Clinical Pharmacology, Odense University
关键词
D O I
10.1111/j.1365-2125.1990.tb03628.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The kinetics at a single oral dose (400 mg) of quinidine were studied in four extensive metabolizers (EM) and four poor metabolizers (PM) of sparteine. The clearance of quinidine by 3‐hydroxylation was significantly lower in PM than in EM, but the difference was small (25‐ 30%). This finding suggests that 3‐hydroxylation, in part, is catalyzed by the same isoenzyme of cytochrome P450, P450db1 which oxidizes sparteine. Otherwise, no significant phenotypic differences in total or metabolic clearance were found and it is concluded that the metabolism of quinidine is largely carried out by P450 isoenzymes different from P450db1. A biexponential decline in the log plasma quinidine concentration vs time curves was observed in all subjects, and the mean elimination half‐life was 11‐12 h. This is about twice as long as generally reported in the literature. 1990 The British Pharmacological Society
引用
收藏
页码:248 / 253
页数:6
相关论文
共 25 条
  • [1] BOOBIS AR, 1988, MICROSOMES DRUG OXID, P216
  • [2] SPARTEINE OXIDATION IS PRACTICALLY ABOLISHED IN QUINIDINE-TREATED PATIENTS
    BRINN, R
    BROSEN, K
    GRAM, LF
    HAGHFELT, T
    OTTON, SV
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (02) : 194 - 197
  • [3] BROSEN K, 1985, ACTA PHARMACOL TOX, V57, P357
  • [4] CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM
    BROSEN, K
    GRAM, LF
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) : 537 - 547
  • [5] BROSEN K, 1987, PHARMACOL TOXICOL, V60, P313
  • [6] DRAYER DE, 1978, CLIN PHARMACOL THER, V24, P31
  • [7] DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT
    EICHELBAUM, M
    SPANNBRUCKER, N
    STEINCKE, B
    DENGLER, HJ
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) : 183 - 187
  • [8] A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION
    EVANS, DAP
    MAHGOUB, A
    SLOAN, TP
    IDLE, JR
    SMITH, RL
    [J]. JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) : 102 - 105
  • [9] CHARACTERIZATION OF THE COMMON GENETIC-DEFECT IN HUMANS DEFICIENT IN DEBRISOQUINE METABOLISM
    GONZALEZ, FJ
    SKODA, RC
    KIMURA, S
    UMENO, M
    ZANGER, UM
    NEBERT, DW
    GELBOIN, HV
    HARDWICK, JP
    MEYER, UA
    [J]. NATURE, 1988, 331 (6155) : 442 - 446
  • [10] GUENGERICH FP, 1986, MOL PHARMACOL, V30, P287